

IMCB Research Excellence Seminar Series



Speaker : Professor Wee Joo Chng
Director, National University Cancer Institute, Singapore
Group Director of Research, National University Health System
Professor & Vice-Dean of Research, Yong Loo Lin School of Medicine
Senior Principal Investigator, Cancer Science Institute of Singapore
Executive Director, Singapore Translational Cancer Consortium

Date : 27 June 2023, Tuesday

Time : 9:30AM - 10:30AM

Venue : IMCB Seminar Room 3-46, Level 3, Proteos, Biopolis

Host : Prof Vinay Tergaonkar

Seminar : Tackling High Risk Myeloma

Myeloma is the second most common hematologic malignancies in the world. Despite improvement in outcomes due to tremendous progress made in drug development in this disease, about 20% of patients still have survival less than 3 years. These high-risk patients are characterized by certain genetic abnormalities, such as t(4;14), t(14;16) or 1q gain or poor clinical behavior (early progression or sub-optimal response to induction treatment) despite a lack of such genetic abnormalities, the so-called functional high-risk patients. In the last few years, our lab has actively pursued research in understanding the effect of these high-risk genetic abnormalities on tumor cell biology and what additional factors may be driving the aggressive and resistant phenotype in the patients with functional high-risk disease. Our studies, take us on an enriching journey in science from transcriptional regulation to cancer metabolism to RNA editing.

About the Speaker :

Professor Wee Joo Chng is Director of the National University Cancer Institute, Singapore and Group Director of Research, at the National University Health System. He is a Yong Loo Lin Professor in Medical Oncology and Vice-Dean of Research of the Yong Loo Lin School of Medicine, and a Senior Principal Investigator of the Cancer Science Institute of Singapore, at the National University of Singapore. He is also the inaugural Executive Director of the Singapore Translational Cancer Consortium. He has authored more than 300 publications, and participates actively in clinical trials, and has delivered talks in many national and international conferences. He has won multiple awards for his research including the NUHS Research Excellence Award, the International Myeloma Foundation's Brian GM Durie Outstanding Achievement Award, the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, NUHS Pinnacle Award for Research Excellence, NUSMed Researcher of the Year, the National University of Singapore Young Researcher Award, and the Celgene Future Leaders in Haematology Award.